A raw, burning fury consumed Elias. He paced the length of his secure office, the plush carpet doing little to cushion his heavy steps. Elara sat hunched over the main monitor, fingers flying across the keyboard, a storm brewing in her own eyes.
Seconds earlier, security footage had shown the masked figure. They’d moved with disturbing familiarity through the hospital’s back corridors, bypassing layers of access control, heading directly for Leo’s room.
“How?” Elara breathed, her voice tight with disbelief. “How did they know the layout so perfectly?”
Elias stopped, his gaze sharp. “Someone inside. Or someone with intimate knowledge of the security schematics.”
His fists clenched. Every failed attempt, every escalation, pointed to a meticulously planned assault. Not just on him, but on his son.
Pulling up a separate console, Elias began cross-referencing recent access logs with known personnel changes. He focused on the past three months, the period coinciding with Leo’s extended stay and the first anonymous threat.
Elara, meanwhile, delved into the pharmacy logs. The mislabeled medication was a glaring red flag. She tracked its journey, from delivery to the moment it appeared on Leo’s tray.
“Look at this,” she muttered, zooming in on a digital signature. “Pharmacist’s ID: Marcus Thorne. He was on vacation.”
Elias spun around. “Vacation? Then someone impersonated him. Or used his credentials.”
Tracing the digital footprint, they found a suspicious login from an unregistered IP address, just hours before the medication incident. The address resolved to a burner phone, untraceable.
“Too clean,” Elias gritted out. “This isn’t some random hacker. This is professional.”
Remembering the anonymous note, Elara started searching for any digital communications tied to Elias’s past, specifically those involving legal disputes or disgruntled parties.
“Think, Elias,” she urged, not looking up. “Who would want to hurt you this deeply? Not just your company, but… Leo?”
His mind raced, sifting through years of cutthroat business dealings. There were many enemies, but none had ever stooped to targeting a child.
Suddenly, Elara froze. Her eyes widened, fixed on a specific email chain from two years ago. “Elias, do you remember Project Chimera?”
He did. A painful memory. Project Chimera was a revolutionary biotech venture, poised to redefine genetic therapies. Elias had invested heavily, only to pull out at the last minute due to a suspicious data breach.
“Of course,” he said, his voice low. “It went under. The lead investor, Julian Vance, lost everything. He vowed to ruin me.”
Vance. Elias had almost forgotten him. A brilliant, ruthless man who saw betrayal in every shadow. Their parting had been acrimonious, filled with threats and legal battles that Elias ultimately won.
“Vance claimed I sabotaged his funding,” Elias continued, a new theory forming. “He believed I stole his research.”
“He didn’t just lose money,” Elara pointed out, scrolling rapidly. “His reputation was destroyed. He disappeared for a while, then resurfaced as a consultant for a rival pharma giant, Cerberus Corp.”
Cerberus Corp. The name sent a chill down Elias’s spine. They were a shadowy conglomerate, known for aggressive, often unethical, corporate espionage.
Rapidly, Elias pulled up Vance’s recent public profiles. He’d gone quiet, but his digital trail showed increasing activity on niche medical forums and scientific journals, particularly those discussing rare genetic disorders.
“This is odd,” Elara murmured, pointing to a series of encrypted messages. “These communications are heavily coded, but they reference ‘Project Chimera’ and ‘leveraging genetic vulnerabilities’.”
They worked in a synchronized frenzy, sifting through the digital debris Vance had left behind. Each click, each decoded phrase, tightened the noose around their former associate.
Grimly, Elias accessed old legal documents. Vance had tried to sue him for intellectual property theft, claiming Elias had stolen his research on specific genetic markers.
“He was obsessed with rare illnesses,” Elias recalled. “He believed curing them was the key to unlocking immense wealth and power, even beyond standard pharma.”
His stomach twisted. Vance’s fixation. Leo’s condition.
Moments later, Elara gasped, her finger trembling on the screen. She’d managed to decrypt a more substantial chunk of Vance’s recent communications with Cerberus Corp. The language was chillingly precise.
“‘The target’s unique genetic profile presents an unparalleled opportunity for corporate leverage,’” she read aloud, her voice barely a whisper. “’The project requires a subject with a specific, rare neurological disorder, similar to condition X, to demonstrate efficacy and destabilize competitors.’”
Condition X. The description matched Leo’s incredibly rare illness perfectly. The same symptoms, the same genetic markers. Vance hadn’t just known about rare illnesses; he had been researching one identical to Leo’s.
Elias felt the air leave his lungs. Vance wasn’t after his company, not primarily. He was after Leo. Using his son’s rare, devastating illness as a weapon in some monstrous corporate game.
A cold, absolute dread settled over them, replacing the fury with a terrifying understanding. Vance hadn't just sought revenge; he had planned a calculated, depraved scheme, using Leo as the ultimate pawn in his twisted pursuit of power.